Dasatinib monohydrate | T1448L | TargetMol Chemicals
Pathway: Angiogenesis|||Apoptosis|||Autophagy|||Cytoskeletal Signaling|||Tyrosine Kinase/Adaptors
Target: Apoptosis|||Bcr-Abl|||Src|||c-Kit|||Ephrin Receptor|||Autophagy
Bioactivity: Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently, because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.
Molecular Weight: 506, 02